The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

The rapid evolution of diabetes research and management calls for a forward-thinking approach that embraces innovation to address the multifaceted ...